Skip to main content Skip to search Skip to main navigation

Swissmedic: Amendment of the Ordinance on In Vitro Diagnostic Medical Devices (IVDs)

The amended Ordinance on In Vitro Diagnostic Medical Devices (IvDO) enters into force on 1 January 2025. Switzerland is implementing extended transitional periods in line with the EU Regulation 2024/1860.

The Regulation has, among other things, extended the validity of certificates issued under the old legislation in the EU to 2027, 2028 or 2029 – depending on risk class – to address bottlenecks at the notified bodies.
The device registration obligation already set out in the Medical Devices Ordinance (MedDO) and IvDO will enter into force from 1 July 2026, six months after the expected registration obligation in EUDAMED.


Source:

Swissmedic: General communications

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB, the European association of medical device Notified Bodies, sees the proposed MDR and IVDR revision as an opportunity to improve efficiency, transparency and predictability in conformity assessment.
Read more
EMA: GMP Documentation for the Sterilisation of an API

EMA: GMP Documentation for the Sterilisation of an API

The EMA Q&A on the quality of medicines has been updated with a new question: “What kind of GMP documentation is required for an API manufacturer performing sterilisation of an active substance?”

Read more
EMA: New Q&A Clarify Regulatory Expectations on API Mixes

EMA: New Q&A Clarify Regulatory Expectations on API Mixes

New Q&A clarify how mixtures of active pharmaceutical ingredients (APIs) and excipients (“API mixes”) should be handled from a regulatory perspective. An API mix is defined as a mixture of an API with one or more excipients and is considered the first step in the manufacture of a finished product.
Read more
Previous
Next